Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus.
The antiviral neuraminidase inhibitor oseltamivir (OSV) is widely used to suppress viral replication in the treatment of influenza. Here, we report that OSV administration significantly suppressed respiratory mucosal secretory IgA responses with respect to antigen (Ag)-specific antibody (Ab) production and also the induction of Ag-specific IgA Ab-forming cells, but not systemic IgG responses, in weanling mice as a model of pediatric influenza. Neutralizing activities of the airway fluids in oral OSV-treated mice were significantly less than those of sham-treated mice. Our findings suggest the risk of re-infection in patients showing a low mucosal response following OSV treatment.
Takahashi
Etsuhisa
E
Division of Enzyme Chemistry, Institute for Enzyme Research, The University of Tokushima, 3-15-18, Kuramoto-cho, Tokushima-city, Tokushima, 770-8503, Japan.
Kataoka
Kosuke
K
Fujii
Kazuyuki
K
Chida
Junji
J
Mizuno
Dai
D
Fukui
Makoto
M
Hiro-O Ito
Fujihashi
Kohtaro
K
Kido
Hiroshi
H
D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D018928:Immunity, Mucosal / Q000187:drug effects; D007070:Immunoglobulin A / Q000276:immunology*; D007074:Immunoglobulin G / Q000276:immunology; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D009980:Influenza A virus / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009976:Orthomyxoviridae Infections / Q000188:drug therapy* / Q000276:immunology*; D053139:Oseltamivir / Q000008:administration & dosage / Q000009:adverse effects*
D000914:Antibodies, Viral; D000998:Antiviral Agents; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D053139:Oseltamivir